Article Text

PDF
Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications

Statistics from Altmetric.com

D P Tashkin

Dr D P Tashkin, University of California, Los Angeles, Los Angeles, CA, USA; dtashkin@mednet.ucla.edu

STUDY DESIGN

Design:

randomised placebo-controlled trial (Understanding Potential Long-Term Impacts on Function with Tiotropium [UPLIFT]). ClinicalTrials.gov NCT00144339.

Allocation concealment:

concealed.*

Blinding:

blinded (clinicians, patients, data collectors, and outcome adjudication committee).*

STUDY QUESTION

Setting:

490 centres in 37 countries worldwide.

Patients:

5993 patients ⩾40 years of age (mean age 65 y, 75% men) who had COPD, a history of ⩾10 pack-years of smoking, and postbronchodilation FEV1 ⩽70% of predicted and ⩽70% of FVC. Exclusion criteria included a history of asthma …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.